Clinical Trial Update: Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia [Phase 3]

View source ↗

Summary

A Phase 3 trial of bendamustine hydrochloride for indolent non-Hodgkin lymphoma and chronic lymphocytic leukemia completed, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Indolent Non-hodgkin Lymphoma

Drugs mentioned

• Bendamustine Hydrochloride (bendamustine)

Snippet

Sponsor: Lundbeck Canada Inc. | Conditions: Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia | Phase 3 | Status: COMPLETED | Results posted: 2014-10-16